Cargando…

262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series

BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Akshay M, Simkins, Jacques, Sinha, Neeraj, Phancao, Anita, Ciancio, Gaetano, Abbo, Lilian M, Guerra, Giselle, Natori, Yoichiro, Anjan, Shweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752877/
http://dx.doi.org/10.1093/ofid/ofac492.340
_version_ 1784850836905525248
author Khatri, Akshay M
Simkins, Jacques
Sinha, Neeraj
Phancao, Anita
Ciancio, Gaetano
Abbo, Lilian M
Guerra, Giselle
Natori, Yoichiro
Anjan, Shweta
author_facet Khatri, Akshay M
Simkins, Jacques
Sinha, Neeraj
Phancao, Anita
Ciancio, Gaetano
Abbo, Lilian M
Guerra, Giselle
Natori, Yoichiro
Anjan, Shweta
author_sort Khatri, Akshay M
collection PubMed
description BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 associated mucormycosis (CAM), but incidence and occurrence in solid organ transplant recipients (SOTRs) is limited. We describe our experience with CFIs in SOTRs with COVID-19. METHODS: In a single center retrospective study at a large volume transplant center in South Florida, USA, we included adult SOTRs (≥18 years) diagnosed with COVID-19 between March 1(st) 2020 and January 31(st) 2022, with subsequent diagnosis of CFI. We collected information related to demographics, comorbidities, COVID-19 diagnosis and therapeutics, and CFI diagnostics and management. Data obtained was analyzed descriptively. RESULTS: We identified 612 SOTRs with COVID-19, of which 23 (3.8%) were diagnosed with CFIs. The patients were predominantly male (17/23, 73.9%), with median age of 59 years (range 43-79) [Table 1]. Twenty (86.9%) were kidney transplant recipients. Majority of SOTRs had lymphopenia (18/23, 78.3%) with elevated inflammatory markers at time of COVID-19 diagnosis. They received most commonly remdesivir and corticosteroids for COVID-19, with 22 (95.6%) needing intensive care unit admission and 19 (82.6%) needing continuous renal replacement therapy. CFIs were diagnosed at median 21 days (range, 3-161) after initial COVID-19 diagnosis. Probable CAPA was diagnosed in most patients (16/23, 69.6%), with CAM noted in 1 patient [Table 2]. 34.8% (8/23) had specific fungal species identified, with elevated fungal markers noted in 95.6% (22/23). Concurrent or prior cytomegalovirus DNAemia was noted in 26.1% (6/23). Patients were followed for median 70 days (range, 19-572), with median hospitalization duration 56 days (range, 7-204). Mortality was noted in 73.9% (17/23). [Figure: see text] [Figure: see text] CONCLUSION: Fungal co-infections were noted in a small proportion of our SOTRs, with poor outcomes. Transplant physicians should have a high suspicion for early diagnosis and treatment of CFI. Further studies are needed to determine predictors for CFI and role for anti-fungal prophylaxis. DISCLOSURES: All Authors: No reported disclosures.
format Online
Article
Text
id pubmed-9752877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97528772022-12-16 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series Khatri, Akshay M Simkins, Jacques Sinha, Neeraj Phancao, Anita Ciancio, Gaetano Abbo, Lilian M Guerra, Giselle Natori, Yoichiro Anjan, Shweta Open Forum Infect Dis Abstracts BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 associated mucormycosis (CAM), but incidence and occurrence in solid organ transplant recipients (SOTRs) is limited. We describe our experience with CFIs in SOTRs with COVID-19. METHODS: In a single center retrospective study at a large volume transplant center in South Florida, USA, we included adult SOTRs (≥18 years) diagnosed with COVID-19 between March 1(st) 2020 and January 31(st) 2022, with subsequent diagnosis of CFI. We collected information related to demographics, comorbidities, COVID-19 diagnosis and therapeutics, and CFI diagnostics and management. Data obtained was analyzed descriptively. RESULTS: We identified 612 SOTRs with COVID-19, of which 23 (3.8%) were diagnosed with CFIs. The patients were predominantly male (17/23, 73.9%), with median age of 59 years (range 43-79) [Table 1]. Twenty (86.9%) were kidney transplant recipients. Majority of SOTRs had lymphopenia (18/23, 78.3%) with elevated inflammatory markers at time of COVID-19 diagnosis. They received most commonly remdesivir and corticosteroids for COVID-19, with 22 (95.6%) needing intensive care unit admission and 19 (82.6%) needing continuous renal replacement therapy. CFIs were diagnosed at median 21 days (range, 3-161) after initial COVID-19 diagnosis. Probable CAPA was diagnosed in most patients (16/23, 69.6%), with CAM noted in 1 patient [Table 2]. 34.8% (8/23) had specific fungal species identified, with elevated fungal markers noted in 95.6% (22/23). Concurrent or prior cytomegalovirus DNAemia was noted in 26.1% (6/23). Patients were followed for median 70 days (range, 19-572), with median hospitalization duration 56 days (range, 7-204). Mortality was noted in 73.9% (17/23). [Figure: see text] [Figure: see text] CONCLUSION: Fungal co-infections were noted in a small proportion of our SOTRs, with poor outcomes. Transplant physicians should have a high suspicion for early diagnosis and treatment of CFI. Further studies are needed to determine predictors for CFI and role for anti-fungal prophylaxis. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752877/ http://dx.doi.org/10.1093/ofid/ofac492.340 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Khatri, Akshay M
Simkins, Jacques
Sinha, Neeraj
Phancao, Anita
Ciancio, Gaetano
Abbo, Lilian M
Guerra, Giselle
Natori, Yoichiro
Anjan, Shweta
262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title_full 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title_fullStr 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title_full_unstemmed 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title_short 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
title_sort 262. covid-19 associated fungal co-infections in solid organ transplant recipients: a single center case series
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752877/
http://dx.doi.org/10.1093/ofid/ofac492.340
work_keys_str_mv AT khatriakshaym 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT simkinsjacques 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT sinhaneeraj 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT phancaoanita 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT cianciogaetano 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT abbolilianm 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT guerragiselle 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT natoriyoichiro 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries
AT anjanshweta 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries